Evidence map›Paper›PMID 35022918›Full record

SynthesisClinical and experimental medicine2022

Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis.

Mao Li, Zhenlu Li, Zihe Wang, Chao Yue, Weiming Hu, Huimin Lu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical and experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mao Li *Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Zhenlu Li *Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Zihe WangDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Chao YueDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Weiming HuDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Huimin LuDepartment of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China. HM.Lu@scu.edu.cn.ORCID http://orcid.org/0000-0002-2532-3362

Funding

1.3.5 project for disciplines of excellence, west china hospital, sichuan university ZYJC18027
6 · The paper itself

Abstract

The systemic immune-inflammation index (SII) is a significant prognostic factor in some cancer types. However, the prognostic value of SII in patients with pancreatic cancer (PC) remains controversial. This study aimed to evaluate the prognostic impact of SII in patients with PC through a meta-analysis. This meta-analysis is aimed to investigate the prognostic significance of SII in patients with PC. Relevant articles were obtained through a systematic search. Hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the association between SII and survival outcomes, including overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and progression-free survival (PFS). Seven studies with 2132 patients were included in the meta-analysis. The results revealed that elevated pretreatment SII was associated with poor OS (HR = 1.55, 95% CI: 1.34-1.78, p < 0.001) and inferior CSS/DFS/PFS (HR = 1.51, 95% CI: 1.27-1.80, p < 0.001). The prognostic role was reliable in a subgroup analysis conducted according to regions, disease status, survival analysis, and cutoff value. High SII was associated with poor OS in patients with PC. Therefore, SII is suggested to be a cost-effective biological marker for monitoring survival in patients with PC.

Indexed as

Pancreatic NeoplasmsBiomarkersHumansInflammationPrognosisBiomarkersMeta-analysisPancreatic cancerPrognosisSurvivalSystemic immune-inflammation index

Identifiers

PMID35022918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.